Attention COVID-19 Survivors: You beat it. Now you could help fight it.
Visit TheFightIsInUs.org now to learn more about the urgent need for you to donate your strength — donate your plasma.

Managing Alpha₁-antitrypsin^* deficiency can feel overwhelming until you have—

a clear path forward.

GLASSIA^® [Alpha₁‑Proteinase Inhibitor (Human)] is used to treat adults with lung disease (emphysema) because of severe Alpha₁‑antitrypsin (AAT) deficiency. GLASSIA is not meant to be used as a therapy in individuals with lung disease other than severe Alpha₁‑PI deficiency.

^*Alpha₁‑antitrypsin is sometimes referred to as just Alpha₁

Want to get updates on Alpha₁ deficiency and GLASSIA?

Get a Clear

Understanding

About Your Condition

The more you know about Alpha₁ deficiency and lung disease (emphysema), the more you’ll understand how important treatment can be.

Alpha₁ is a protein that helps protect the lungs

Alpha₁ circulates in your bloodstream and helps protect the elastic structures of your lungs from an enzyme that can attack normal body tissue. Without enough functional Alpha₁, lung damage can develop, usually in people between 20 and 50 years of age.

Emphysema can be caused by a severe Alpha₁ deficiency

A severe Alpha₁ deficiency can lead to emphysema—a lung condition that causes shortness of breath—with symptoms that can worsen over time.

Alpha₁ deficiency can run in families

Alpha₁ deficiency is caused by a genetic mutation that occurs in about 1 of every 3,000 to 5,000 people in the U.S. It’s also the most common genetic cause of emphysema.

Know this:

you’re not alone.

1 In Every
3,000 – 5,000

Americans lives with Alpha₁ deficiency.

Talk to your doctor if you have questions about family testing, living with Alpha₁ deficiency, or augmentation therapy.

Start Your

Treatment

With Clarity

Know how GLASSIA works. Know what treatment experience works best for you.

GLASSIA INCREASES THE LEVELS OF THE ALPHA₁ PROTEIN IN YOUR BLOOD AND LUNGS

The Alpha₁ protein protects the lung tissue by blocking certain enzyme-caused damage. Such damage can lead to severe lung disease, such as emphysema.

Alpha₁ augmentation is chronic maintenance therapy. So, GLASSIA is typically given once every week to increase levels of Alpha₁ in your blood and lungs.

GLASSIA is ready to infuse

GLASSIA is an intravenous (into a vein) infusion that generally takes about 15 minutes at the recommended dose and maximum infusion rate.

GLASSIA puts you in control of your infusion experience

GLASSIA’s flexibility of administration lets you decide where you want to infuse. Talk to your healthcare provider about which administration option works best for you:

In the clinic by a healthcare provider
At an outpatient infusion center
At home by a healthcare provider
At home through self-infusion or by a caregiver—after appropriate training^†

^†If self-administration is deemed appropriate, ensure that you receive detailed instructions and adequate training on how to administer at home or other appropriate setting and have demonstrated the ability to independently administer GLASSIA.

The first FDA‑approved

Liquid Alpha₁ augmentation therapy, GLASSIA has been prescribed by pulmonologists for 10 years running.

Talk to your doctor about GLASSIA.

Keep Moving Forward With

OnePath^®

Know that OnePath is here for you after you and your physician choose your treatment path.

Personalized product support from OnePath

After you enroll in OnePath, you will receive a dedicated Patient Support Manager who will be your main point of contact throughout your treatment journey.^‡ Your Patient Support Manager will work with you one-on-one to make sure you have access to your prescribed Takeda medication.

He or she will help you navigate many different aspects of your therapy, from insurance and financial options to training and prescription fulfillment.

OnePath helps you:

Navigate the health insurance process
Enroll in the OnePath Co-Pay Assistance Program (if eligible) or discuss financial assistance options
Coordinate medication delivery with your specialty pharmacy
Receive free self-administration training with a nurse (if applicable)
Learn about additional support, education, and community resources

ONEPATH CO-PAY ASSISTANCE PROGRAM

The OnePath Co-Pay Assistance Program helps cover certain out-of-pocket treatment costs for eligible, commercially insured patients who are enrolled in OnePath.

The following are covered up to the program maximum and may be paid directly to the provider:

100% coverage of eligible out-of-pocket costs, which may include deductibles, co-pays, and co-insurance^§
Out-of-pocket cost of eligible infusion charges where applicable by law

At a minimum, to be eligible for the program, a patient must:

Be enrolled in OnePath
Have commercial insurance
Other eligibility requirements apply.^‖ For more information, please contact a OnePath Patient Support Manager at 1‑866‑888‑0660.

^‡OnePath is open to all patients taking GLASSIA for its indicated use and who complete the GLASSIA OnePath Start Form, which provides OnePath with your consent to provide product support.

^§Subject to program terms, limits, and conditions

^‖Additional program restrictions and eligibility requirements apply. Not valid for prescriptions eligible to be reimbursed by Medicaid, Medicare, or other state or federal programs. Offer good only in the United States. Offer void where prohibited by law, taxed, or restricted. Takeda reserves the right to rescind, revoke, or amend this offer at any time without notice.

PATIENT SUPPORT MANAGERS ARE READY TO ASSIST YOU.

Call OnePath at 1-866-888-0660. OnePath is available Monday through Friday, 8:30 AM to 8:00 PM ET. Keep the OnePath number (1-866-888-0660) in your phone so you don’t confuse us with spam calls. If you miss a call from us, please call us back. If you give us permission, we can leave a voicemail saying why we called.

Visit OnePath.com

Stay

in touch

Are you a:

Patient

Caregiver

By checking this box and selecting "Sign me up," you certify that you are at least 18 years old and you are opting to receive information about GLASSIA, alpha₁‑antitrypsin deficiency, and other information from Takeda and its contracted partners. Takeda and its contracted partners respect your privacy. You may unsubscribe from these communications at any time by clicking on the Unsubscribe link in the email communication.^*

By providing your personal and/or medical data and clicking on the "Sign me up" button, you authorize Takeda to provide you with information, resources, services and communication via email or direct mail. Takeda respects your personal information. All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our Privacy Notice. We encourage you to read our Privacy Notice by clicking on this link: Privacy Notice. This consent will be in effect until such time as you opt out.

^*Required

What is GLASSIA?

GLASSIA is a medicine containing human Alpha₁-Proteinase Inhibitor (Alpha₁-PI) also known as alpha₁-antitrypsin (AAT) and is used to treat adults with lung disease (emphysema) because of severe Alpha₁ antitrypsin (AAT) deficiency. GLASSIA is not meant to be used as a therapy in individuals with lung disease other than severe Alpha₁-PI deficiency.

Expand+

Important Safety Information

What is the most important information I need to know about GLASSIA?

GLASSIA can cause severe allergic reactions including hives, swelling in the mouth or throat, itching, tightness in the chest, trouble breathing, wheezing, faintness or low blood pressure
If you will be taking GLASSIA outside a healthcare setting, ask your healthcare provider (HCP) about an epinephrine pen and/or other supportive care for certain severe allergic reactions.

Who should not use GLASSIA?

Do not use GLASSIA if you:

Have immunoglobulin A (IgA) deficiency with antibodies to IgA
Have a severe allergic reaction to human Alpha₁-PI products.

What are the possible or reasonably likely side effects of GLASSIA?

If any of the following problems occur contact your healthcare provider (HCP) or call emergency services right away:

Worsening or flare-up of your chronic obstructive pulmonary disease (COPD)
Hives, swelling in the mouth or throat, itching, chest tightness, trouble breathing, wheezing, fainting or dizziness. These could be signs of a serious allergic reaction.

The most common side effects that may occur are headache and upper respiratory tract infections

Other possible side effects of GLASSIA include:

Cough
Sinus infection
Chest discomfort
Dizziness
Increased liver enzymes
Shortness of breath
Nausea
Fatigue

These are not all the possible side effects. Tell your HCP about any side effect that bothers you or that does not go away.

For additional safety information, click for Information For Patients including Instructions For Use and discuss with your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.